Molecular Mechanisms of the Medicines for COVID-19

被引:22
|
作者
Komiyama, Makoto [1 ]
机构
[1] Univ Tokyo, Res Ctr Adv Sci & Technol RCAST, Meguro Ku, 4-6-1 Komaba, Tokyo 1538904, Japan
关键词
COVID-19; Medicine; Enzyme inhibitor; RECEPTOR-BINDING DOMAIN; PAPAIN-LIKE PROTEASE; SARS-COV-2; RNA; NANOMATERIALS; INHIBITION; DISCOVERY;
D O I
10.1246/bcsj.20220179
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
For these three years, COVID-19 has globally spread and caused enormous damage all over the world. Although vaccines served to reduce its infection, their effects are still limited mainly due to rapid and vigorous mutations of SARS-CoV-2 virus. In order to bring this pandemic under control, we must develop novel medicines which are easily administered when needed and very effective without undesired side-effects. In this account, the developments of specific medicines for COVID-19 are surveyed with the emphasis on the molecular mechanisms of their therapeutic actions. Most of them are inhibitors of enzymes, which are indispensable for the virus, but unnecessary for human beings. These inhibitors selectively hamper the critical steps for viral proliferation (viral entry to human cells, replication of RNA genome, production of viral proteins, and others). There have been several successful examples, which are already approved as medicines for the treatment of COVID-19. Unfortunately, however, few of them sufficiently satisfy all the requirements to overcome this unprecedented pandemic completely, and thus further innovation is necessary.
引用
收藏
页码:1308 / 1317
页数:10
相关论文
共 50 条
  • [21] Medicines for the Treatment Of COVID-19: Awaiting the Evidence
    Marto, Natalia
    Monteiro, Emilia C.
    ACTA MEDICA PORTUGUESA, 2020, 33 (7-8) : 500 - 504
  • [22] An Overview of COVID-19 Medicines in Current Guidelines
    Gokce, Mustafa
    Guler, Eray Metin
    BEZMIALEM SCIENCE, 2020, 8 : 99 - 104
  • [23] COVID-19 Treatment Repurposing ayurvedic medicines
    不详
    CURRENT SCIENCE, 2021, 120 (10): : 1552 - 1552
  • [24] COVID-19 Pandemic: A Surge in Counterfeit Medicines
    Ussai, S.
    DRUG SAFETY, 2022, 45 (10) : 1181 - 1181
  • [25] COVID-19 infection and medicines in pregnancy in Canada
    Berard, Anick
    Sheehy, Odile
    Kaul, Padma
    Eltonsy, Sherif
    Walker, Mark
    Hawken, Steven
    Bernatsky, Sasha
    Pugliese, Michael
    Barrett, Olesya
    Savu, Anamaria
    Dragan, Roxana
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 200 - 200
  • [26] COVID-19 Infection and Medicines in Pregnancy in Canada
    Berard, A.
    Sheehy, O.
    Kaul, P.
    Eltonsy, S.
    Walker, M.
    Hawken, S.
    Bernatsky, S.
    Pugliese, M.
    Barrett, O.
    Savu, A.
    Dragan, R.
    EUROPEAN PSYCHIATRY, 2024, 67 : S106 - S107
  • [27] COVID-19 Infection and Medicines in Pregnancy in Canada
    Berard, A.
    Sheehy, O.
    Kaul, P.
    Eltonsy, S.
    Walker, M.
    Hawken, S.
    Bernatsky, S.
    Pugliese, M.
    Barrett, O.
    Savu, A.
    Dragan, R.
    BIRTH DEFECTS RESEARCH, 2023, 115 (08): : 888 - 888
  • [28] Immunosuppression for COVID-19: repurposing medicines in a pandemic
    Shivakumar, Senthuran
    Smibert, Olivia C.
    Trubiano, Jason A.
    Frauman, Albert G.
    Liew, David F. L.
    AUSTRALIAN PRESCRIBER, 2020, 43 (04) : 106 - 107
  • [29] Periodontitis and COVID-19: mechanisms
    Reena Wadia
    British Dental Journal, 2022, 233 (4) : 286 - 286
  • [30] Mechanisms of immunothrombosis in COVID-19
    Portier, Irina
    Campbell, Robert A.
    Denorme, Frederik
    CURRENT OPINION IN HEMATOLOGY, 2021, 28 (06) : 445 - 453